Rhodiolae Crenulatae Radix et Rhizoma protects brain microvascular endothelial cells from ischemia and hypoxia injury by regulating PI3K/AKT/GSK3β pathway.
10.19540/j.cnki.cjcmm.20250219.401
- Author:
Li TANG
1
;
Qiu-Yue YANG
1
;
Hong-Fa CHENG
1
;
Ya-Hui XIE
1
;
Qiu-Xia ZHANG
1
Author Information
1. School of Traditional Chinese Medicine, Capital Medical University Beijing 100069, China Beijing Key Laboratory of Traditional Chinese Medcine Collateral Disease Theory Research Beijing 100069, China.
- Publication Type:Journal Article
- Keywords:
PI3K/AKT/GSK3β pathway;
Rhodiolae Crenulatae Radix et Rhizoma;
cerebral microvascular endothelial cells;
network pharmacology
- MeSH:
Endothelial Cells/cytology*;
Glycogen Synthase Kinase 3 beta/genetics*;
Proto-Oncogene Proteins c-akt/genetics*;
Drugs, Chinese Herbal/pharmacology*;
Phosphatidylinositol 3-Kinases/genetics*;
Signal Transduction/drug effects*;
Brain/metabolism*;
Humans;
Animals;
Rhizome/chemistry*;
Microvessels/metabolism*;
Brain Ischemia/drug therapy*
- From:
China Journal of Chinese Materia Medica
2025;50(11):3127-3136
- CountryChina
- Language:Chinese
-
Abstract:
This study elucidates the mechanism of Rhodiolae Crenulatae Radix et Rhizoma(RCRR) in protecting brain microvascular endothelial cells from oxygen-glucose deprivation(OGD) injury and reveals the modern pharmacological mechanism of RCRR's traditional use in nourishing Qi and promoting blood circulation to protect endothelial cells. The scratch assay was employed to assess the migratory capacity of endothelial cells. Immunofluorescence and Western blot techniques were employed to assess the protein expression of tight junction proteins zonula occludens-1(ZO-1), occludin, claudin-5, and proteins of the phosphoinositide 3-kinase(PI3K)/protein kinase B(AKT)/glycogen synthase kinase-3beta(GSK3β) pathway. The results demonstrated that 63 bioactive components and 125 potential core targets of RCRR were identified from the ETCM, TCMBank, and SwissTargetPrediction databases, as well as from the literature. A total of 1 708 brain microvascular endothelial cell-related targets were identified from the GeneCards and OMIM databases, and 52 targets were obtained by intersecting drug components with cell targets. The protein-protein interaction(PPI) network analysis revealed that AKT1, epidermal growth factor receptor(EGFR), matrix metalloproteinase 9(MMP9), estrogen receptor 1(ESR1), proto-oncogene tyrosine-protein kinase(SRC), peroxisome proliferator-activated receptor gamma(PPARG), GSK3β, and matrix metalloproteinase 2(MMP2) were considered hub genes. The KEGG enrichment analysis identified the PI3K/AKT pathway as the primary signaling pathway. Cell experiments demonstrated that RCRR-containing serum could enhance the migratory capacity of brain microvascular endothelial cells and the expression of tight junction proteins following OGD injury, which may be associated with the downregulation of the PI3K/AKT/GSK3β pathway. This study elucidates the pharmacological mechanism of RCRR in protecting brain microvascular endothelial cells through network pharmacology, characterized by multiple components and targets. These findings were validated through in vitro experiments and provide important ideas and references for further research into the molecular mechanisms of RCRR in protecting brain microvascular endothelial cells.
